You are here

Article info

Article menu

Download PDFPDF

Oncolytic and local immunotherapy
Original research
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

Authors

  • Praveen K Bommareddy Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Brain Tumor Research Center, Boston, Massachusetts, USACancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, USA PubMed articlesGoogle scholar articles
  • Hiroaki Wakimoto Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Brain Tumor Research Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Robert L Martuza Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Brain Tumor Research Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Howard L Kaufman Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Brain Tumor Research Center, Boston, Massachusetts, USADepartment of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Samuel D Rabkin Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Brain Tumor Research Center, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Dipongkor Saha Department of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy, Elk Grove, California, USADepartment of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, USA PubMed articlesGoogle scholar articles

Citation

Bommareddy PK, Wakimoto H, Martuza RL, et al
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
Journal for ImmunoTherapy of Cancer 2024;12:e008880. doi: 10.1136/jitc-2024-008880
Online issue publication 
April 09, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.